Foghorn Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $36.7M+62.5% YoYTTM through 30 Jun 2026
Net Income -$64.6MTTM through 30 Jun 2026
Free Cash Flow -$84.3MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 89.3% |
| EBITDA Margin | -192.3% |
| Operating Margin | -265.7% |
| Net Margin | -175.8% |
Returns
79.7%ROE
-31.8%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio3.36x
Net Debt-$158.9Mnet cash position
Cash & Equivalents$68.1M
Quality Metrics
Altman Z-Score-4.30
Piotroski F-Score3 / 9
FCF Margin-229.4%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $30.9M
Diluted EPS-$0.99TTMFY2025: $-1.18
Dividend
No dividend
Capital Allocation
Capex Intensity0.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Collaboration | $30.9M | +36.7% | View detailsRevenue is driven by the continued advancement of partnered programs, including the Phase 1 dose escalation study of FHD-909. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.